Literature DB >> 24002436

Identification of cancer stem cells from hepatocellular carcinoma cell lines and their related microRNAs.

Yangmei Xu1, Yunqing Xie, Xiangru Wang, Xuefang Chen, Qingyin Liu, Mingang Ying, Qiuhong Zheng.   

Abstract

The aim of this study was to identify cancer stem cells (CSC) from three hepatocellular carcinoma (HCC) cell lines and to screen for specific microRNAs (miRNAs) regulating CSCs. Side population (SP) phenotype analysis was used. Four factors in the staining process, the incubation time, shaking interval, culture time and Hoechst 33342 concentration were explored, respectively, to define the SP subtype. CSC characteristics of SP cells were verified by sphere-forming assay and tumorigenic ability in NOD/SCID mice. QPCR assay for 370 miRNAs was performed to identify the differential miRNA expression between SP and Non-SP (NSP) cells in the PLC/PRF/5 cell line. The selected miRNAs were tested again in SP and NSP cells from Huh-7 and Hep-3B cell lines by qPCR assay. All four factors influenced SP percentage, when the other three conditions were fixed, the optimal Hoechst 33342 concentrations determined were 11 µg/ml for PLC/PRF/5 cells, 4 µg/ml for Huh-7 and 5 µg/ml for Hep-3B cells. The resultant SP percentage was 0.73±0.12%, 0.49±0.04% and 0.63±0.08%, respectively. The purity of sorted SP cells was >85%. Floating spheres were formed by SP cells from all three cell lines, while NSP cells did not form a single floating sphere. Mice injected with SP cells on the right side formed more tumor masses compared to their counterpart NSP at the same injection dosage; qPCR profiling identified 27 differentially expressed miRNAs in PLC/PRF/5 cells. Subsequent qPCR assay showed that miR-9* and miR-194 were also downregulated in SP cells from Huh-7 and Hep-3B. The present study identified CSCs via SP and sphere-forming assay from three liver cancer cell lines. Altogether, 27 CSC-specific miRNAs were determined in PLC/PRF/5; miR-9* and miR-194 were identified as the common CSC-specific miRNAs across the three HCC cell lines.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24002436     DOI: 10.3892/or.2013.2703

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  5 in total

1.  Overexpression of DDIT4 and TPTEP1 are associated with metastasis and advanced stages in colorectal cancer patients: a study utilizing bioinformatics prediction and experimental validation.

Authors:  Fahimeh Fattahi; Jafar Kiani; Mahdi Alemrajabi; Ahmadreza Soroush; Marzieh Naseri; Mohammad Najafi; Zahra Madjd
Journal:  Cancer Cell Int       Date:  2021-06-09       Impact factor: 5.722

2.  miRNA-148b suppresses hepatic cancer stem cell by targeting neuropilin-1.

Authors:  Qinying Liu; Yangmei Xu; Shenghong Wei; Wei Gao; Li Chen; Tong Zhou; Zhen Wang; Mingang Ying; Qiuhong Zheng
Journal:  Biosci Rep       Date:  2015-05-22       Impact factor: 3.840

Review 3.  The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review.

Authors:  Rafael Valencia-Quintana; Juana Sánchez-Alarcón; María G Tenorio-Arvide; Youjun Deng; José M R Montiel-González; Sandra Gómez-Arroyo; Rafael Villalobos-Pietrini; Josefina Cortés-Eslava; Ana R Flores-Márquez; Francisco Arenas-Huertero
Journal:  Front Microbiol       Date:  2014-03-18       Impact factor: 5.640

4.  Comparative proteomics of side population cells derived from human hepatocellular carcinoma cell lines with varying metastatic potentials.

Authors:  Hongzhi Liu; Yingchao Wang; Xiaohua Xing; Ying Sun; Dahai Wei; Geng Chen; Qinying Liu; Shanshan Chen; Xiaolong Liu; Jingfeng Liu
Journal:  Oncol Lett       Date:  2018-05-08       Impact factor: 2.967

5.  Co-regulatory Network of Oncosuppressor miRNAs and Transcription Factors for Pathology of Human Hepatic Cancer Stem Cells (HCSC).

Authors:  Rania Hassan Mohamed; Nourhan Abu-Shahba; Marwa Mahmoud; Ahmed M H Abdelfattah; Wael Zakaria; Mahmoud ElHefnawi
Journal:  Sci Rep       Date:  2019-04-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.